Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | DAO | P14920 | 5/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8935164 | 0.98 | GSK3B (0.59) | GSK3BMEN1KMT2ADAOGPR35 | |
| Hydrochloric Acid SCHEMBL8935203 | 0.98 | GSK3B (0.59) | GSK3BMEN1KMT2ADAOGPR35 | |
| 4-Bromoaniline SCHEMBL9422575 | 0.84 | MEN1 (0.54) | GSK3BMEN1KMT2ADAOGPR35 | |
| SCHEMBL7043189 | 0.82 | GSK3B (0.57) | GSK3BMEN1KMT2ADAOALDH1A1 | |
| SCHEMBL8651250 | 0.81 | GSK3B (0.61) | GSK3BMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7892619 | 0.79 | GSK3B (0.62) | GSK3BMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2043829 | 0.79 | GSK3B (0.59) | GSK3BMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5010509 | 0.79 | GSK3B (0.59) | GSK3BMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL17201685 | 0.79 | DAO (0.45) | GSK3BMEN1KMT2ADAOGPR35 | |
| SCHEMBL30020630 | 0.79 | GPR35 (0.48) | GSK3BMEN1KMT2ADAOGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | claimed |
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | claimed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
| EP-4132508-B1 | NOVEL INHIBITORS OF HISTONE ACETYLTRANSFERASE P300/CBP FOR CANCER THERAPY | BAYLOR COLLEGE MEDICINE (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250296926-A1 | SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2025-09-25 | — | — | US | disclosed |
| EP-0379003-A1 | Thiophene-2-carboxylic-acid derivatives, process for their preparation and their use in combating undesired plant growth | BASF Aktiengesellschaft (DE) | 1990-07-25 | — | — | EP | disclosed |
| US-3887354-A | Method for facilitating the harvest of fruit | MONSANTO CO | 1975-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | GSK3B 308/4885MEN1 2054/4885KMT2A 2920/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | GSK3B 4021/4885MEN1 3024/4885KMT2A 1833/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | GSK3B 938/4885MEN1 3962/4885KMT2A 618/4885 |
| US-20250296926-A1 | SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELS | GRIK4, GRIK2, GRIK1 | GSK3B 1751/4885MEN1 3693/4885KMT2A 2424/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | GSK3B 474/4885MEN1 3396/4885KMT2A 2410/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | GSK3B 308/4885MEN1 2054/4885KMT2A 2920/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | GSK3B 308/4885MEN1 2054/4885KMT2A 2920/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | GSK3B 308/4885MEN1 2054/4885KMT2A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.